Part 1. Introduction

• 1.1 Market Definition
• 1.2 Key Benefit
• 1.3 Market Segment

Part 2. Methodology

• 2.1 Primary
• 2.2 Secondary

Part 3. Executive Summary

Part 4. Market Overview

• 4.1 Introduction
• 4.2 Market Size and Forecast
• 4.3 Market Dynamics
  • 4.3.1 Drivers
  • 4.3.2 Restraints
• 4.4 Impact of COVID-19 Pandemic on Global Economy
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Bargaining Power of Suppliers
  • 4.5.2 Bargaining Power of Consumers
  • 4.5.3 Threat of New Entrants
  • 4.5.4 Threat of Substitute Products and Services
  • 4.5.5 Degree of Competition

Part 5. Global Market for Human Albumin by Application

• 5.1 Market Overview
• 5.2 Therapeutics
  • 5.2.1 Market Size and Forecast
• 5.3 Drug Formulation & Vaccine
  • 5.3.1 Market Size and Forecast
• 5.4 Others
  • 5.4.1 Market Size and Forecast

Part 6. Global Market for Human Albumin by Geography

• 6.1 Overview
  • 6.1.1 Market Size and Forecast
• 6.2 North America
  • 6.2.1 Market Size and Forecast
  • 6.2.2 North America: Human Albumin Market by Country
    • 6.2.2.1 United States
    • 6.2.2.2 Canada
    • 6.2.2.3 Mexico
• 6.3 Europe
  • 6.3.1 Market Size and Forecast
  • 6.3.2 Europe: Human Albumin Market by Country
    • 6.3.2.1 Germany
    • 6.3.2.2 France
    • 6.3.2.3 United Kingdom
    • 6.3.2.4 Italy
    • 6.3.2.5 Rest of The Europe
• 6.4 Asia-Pacific
  • 6.4.1 Market Size and Forecast
  • 6.4.2 Asia-Pacific: Human Albumin Market by Country
    • 6.4.2.1 China
    • 6.4.2.2 India
    • 6.4.2.3 Japan
    • 6.4.2.4 South Korea
    • 6.4.2.5 ASEAN Countries
• 6.5 Middle East and Africa (MEA)
  • 6.5.1 Market Size and Forecast
  • 6.5.2 MEA: Human Albumin Market by Country
    • 6.5.2.1 Saudi Arabia
    • 6.5.2.2 South Africa
    • 6.5.2.3 Turkey
• 6.6 South America
  • 6.6.1 Market Size and Forecast
  • 6.6.2 South America: Human Albumin Market by Country
    • 6.6.2.1 Brazil
    • 6.6.2.2 Argentina
    • 6.6.2.3 Rest of South America

  Part 7. Competitive Landscape

  • 7.1 Market Share
  • 7.2 Mergers & Acquisitions, Agreements, Collaborations and Partnerships

  Part 8. Key Competitor Profiles

  • 8.1 CSL Behring
  • 8.2 Octapharma AG
  • 8.3 Biotest AG
  • 8.4 Kedrion Biopharma Inc.
  • 8.5 Baxter International Inc.
  • 8.6 LFB Biomedicaments SA
  • 8.7 Grifols, S.A.
  • 8.8 NOVA Biologics, Inc.
  • 8.9 China Biologic Products Holdings, Inc.
  • 8.10 Sanquin Plasma Products BV (SPP)
  • 8.11 Novozymes A/S
  • 8.12 Shire Pharmaceutical Holdings Ireland Limited
  • 8.13 Huanlan Biological Engineering Inc.
  • 8.14 Jiangxi Boya Bio pharmaceutical Group Co., Ltd.
  • 8.15 Beijing Tiantan Biological Products Co., Ltd.

  *LIST IS NOT EXHAUSTIVE

  Part 9. Patent Analysis

  • 9.1 Patent Statistics
  • 9.2 Regional Analysis
  • 9.3 Trends Analysis

  DISCLAIMER

  ABOUT GEN CONSULTING COMPANY

The human albumin market is expected to grow by USD 1098.75 million during 2020-2026, according to the latest research report by Gen Consulting Company.

The report offers a breakdown of market shares by application, including Therapeutics, Drug Formulation & Vaccine, Others. On the basis of region, the human albumin industry is analyzed across North America, Europe, Asia-Pacific, South America and MEA (the Middle East, and Africa).

By Application:
- Therapeutics
- Drug Formulation & Vaccine
- Others

By region, the market is analyzed across North America, Asia Pacific, Europe, Middle East & Africa and South America. This report forecasts revenue growth at global, regional & country level from 2020 to 2026.
- North America (U.S., Canada, Mexico, etc.)
- Asia-Pacific (China, Japan, India, Korea, Australia, Indonesia, Taiwan, Thailand, etc.)
- Europe (Germany, UK, France, Italy, Russia, Spain, etc.)
- Middle East & Africa (Turkey, Saudi Arabia, Iran, Egypt, Nigeria, UAE, Israel, South Africa, etc.)
- South America (Brazil, Argentina, Colombia, Chile, Venezuela, Peru, etc.)

The market research report covers the analysis of key stake holders of the human albumin market. Some of the leading players profiled in the report include:
- CSL Behring
- Octapharma AG
- Biotest AG
- Kedrion Biopharma Inc.
- Baxter International Inc.
- LFB Biomedicaments SA
- Grifols, S.A.
- NOVA Biologics, Inc.
- China Biologic Products Holdings, Inc.
- Sanquin Plasma Products BV (SPP)
- Novozymes A/S
- Shire Pharmaceutical Holdings Ireland Limited
- Huanlan Biological Engineering Inc.
- Jiangxi Boya Bio pharmaceutical Group Co., Ltd.
- Beijing Tiantan Biological Products Co., Ltd.
*list is not exhaustive, request free sample to get a complete list of companies

The base year of the study is 2019, and forecasts run up to 2026.

Research Objective
- To analyze and forecast the market size of global human albumin market.
- To classify and forecast global human albumin market based on application.
- To identify drivers and challenges for global human albumin market.
- To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in global human albumin market.
- To conduct pricing analysis for global human albumin market.
- To identify and analyze the profile of leading players operating in global human albumin market.

The report is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities. Key target audience are:
- Manufacturers of human albumin
- Raw material suppliers
- Market research and consulting firms
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to human albumin